Castle Biosciences, Inc. - CSTL STOCK NEWS

Castle Biosciences (Nasdaq: CSTL) has announced its sponsorship of the 71st Annual Montagna Symposium on the Biology of the Skin, scheduled for Oct. 17-21, 2024, in Stevenson, Washington. The event, hosted by the Oregon Health & Science University Department of Dermatology, aims to bring together clinicians and scientists to explore focused aspects of dermatology and skin biology.

Dr. Matthew Goldberg, SVP of medical at Castle Biosciences, expressed pride in supporting the symposium's mission to exchange knowledge and integrate recent discoveries into clinical practice. The Montagna Symposium, established in 1950, has attracted over 5,000 attendees and serves as a platform for new concepts in cutaneous biology.

This year's symposium will focus on skin of color dermatology, covering topics such as genetics, social determinants of health, and cutaneous disorders affecting people with pigmented skin. Dr. Tamia Harris-Tryon, the symposium program chair, highlighted the importance of support from organizations like Castle Biosciences in challenging disease management paradigms for improved patient care.

Castle Biosciences announced new data presentations for its DecisionDx-Melanoma and DecisionDx-UM tests at the 21st International Congress of the Society for Melanoma Research (SMR). A prospective, multicenter study of 876 patients with Stage I-III cutaneous melanoma showed that DecisionDx-Melanoma significantly stratified patients by recurrence risk and added prognostic value to AJCC staging. Patients with Class 1A results had higher three-year recurrence-free survival compared to Class 1B/2A or 2B (p<0.001).

The company will also present data on DecisionDx-UM for uveal melanoma, confirming PRAME status as a risk modifier. Castle Biosciences' CEO Derek Maetzold stated that their tests provide clinical value beyond current staging methods, enabling improved risk-aligned treatment decisions associated with better outcomes.

Castle Biosciences (Nasdaq: CSTL) announced a groundbreaking ceremony for its new corporate headquarters in Friendswood, Texas. The event, scheduled for Oct. 22, 2024, marks the start of construction on a four-story, 80,000 square foot Class A office building. The 23-acre campus will feature amenities like a covered rooftop deck, corporate fitness center, walking trails, and covered pavilions.

Derek Maetzold, CEO of Castle Biosciences, emphasized the company's commitment to its employees and the community. The new facility is designed to foster collaboration and support future growth. Jason Tramonte Jr., the project's architect, highlighted the employee-centric focus in the design. Castle Biosciences, founded in 2008, also operates clinical laboratories in Phoenix and Pittsburgh.

Castle Biosciences (Nasdaq: CSTL) announced new data demonstrating the effectiveness of its DecisionDx-SCC test in risk stratification for high-risk cutaneous squamous cell carcinoma (SCC) patients, particularly those with suppressed immune systems. The data, to be presented at the ASTRO 2024 Annual Meeting, shows that the test can guide treatment intensification decisions, such as adjuvant radiation therapy.

The study analyzed 954 SCC patients with at least one NCCN high-risk factor. For patients with BWH T1 tumors, the DecisionDx-SCC test further stratified risk regardless of immune status. For immune suppressed patients with T2a tumors, the test identified those with more favorable (Class 1) and less favorable (Class 2A/2B) survival rates. The results suggest that treatment intensification should be considered for immune suppressed patients with BWH T2a SCC tumors, guided by DecisionDx-SCC test results.

Castle Biosciences will present new data on its TissueCypher Barrett's Esophagus test at the American Foregut Society 2024 Annual Meeting. The data demonstrates the test's ability to independently predict the risk of esophageal cancer progression in patients with Barrett's esophagus (BE).

Key findings include:

• TissueCypher alone is the strongest predictor of progression to esophageal cancer, outperforming combinations with clinicopathologic risk factors.
• For non-dysplastic BE patients, TissueCypher was the only significant predictor of progression.
• The test guided risk-aligned management decisions in 86% of patients, leading to upstaged management in 21% and supporting long-interval surveillance in 90% of low-risk patients.

These results highlight TissueCypher's clinical value in identifying high-risk patients and tailoring treatment plans based on cancer progression likelihood.

Castle Biosciences (Nasdaq: CSTL) announced that its Chief Operating Officer, Kristen Oelschlager, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by the Arizona Bioindustry Association (AZBio). Oelschlager, a registered nurse with over 15 years of experience in clinical nursing, operations services, and research, is recognized for her significant contributions to the progression of the bioscience industry in Arizona.

As a co-founder of Castle Biosciences in 2008, Oelschlager has played a important role in the company's growth and success. Castle Biosciences specializes in innovative testing solutions to guide treatment decisions for cancer patients. The award will be presented at the AZBio Awards on September 18, 2024, at the Phoenix Convention Center.

Castle Biosciences (Nasdaq: CSTL) has published a new study in the World Journal of Surgical Oncology, demonstrating the effectiveness of their DecisionDx-Melanoma test in predicting sentinel lymph node (SLN) positivity risk. The study shows that the test can help reduce unnecessary sentinel lymph node biopsy (SLNB) surgeries by 33% in patients with T1-T2 melanoma tumors.

Key findings include:

• None of the patients classified as low-risk by DecisionDx-Melanoma had a positive SLN
• 31.9% SLN positivity rate in patients predicted to have >10% risk
• Potential SLNB reduction rate of 33% in patients with AJCC8 T1-T2 tumors

The study suggests that DecisionDx-Melanoma can improve patient selection for SLNB procedures, potentially reducing healthcare costs and unnecessary surgeries while maintaining good patient outcomes.

Castle Biosciences (Nasdaq: CSTL) has published a new study in Future Oncology validating the use of its DecisionDx-SCC test for guiding adjuvant radiation therapy (ART) decisions in high-risk cutaneous squamous cell carcinoma (SCC) patients. The study, involving 399 patients and 423 tumors, showed that:

1. Patients with Class 2B results (highest metastatic risk) treated with ART had a 50% decrease in metastatic disease progression.
2. Patients with Class 1 results (lowest metastatic risk) showed no difference in disease progression with or without ART, suggesting they may defer treatment.
3. Class 2A patients showed no significant benefit from ART despite intermediate risk levels.

This study corroborates findings from a recent 2024 study, further supporting DecisionDx-SCC's ability to improve risk-aligned patient care through precise, tumor-biology-based risk stratification.

Castle Biosciences (Nasdaq: CSTL), a company specializing in innovative health tests, has announced its participation in two upcoming investor conferences. The company's executive management will present a company overview at Baird's 2024 Global Healthcare Conference on September 11, 2024, at 9:05 a.m. Eastern time. A live audio webcast of this presentation will be available on Castle Biosciences' website, with a replay accessible afterwards.

Additionally, Castle Biosciences will be available for one-on-one investor meetings during the 8th Annual Lake Street Best Ideas Growth (BIG8) Conference on September 12, 2024. Interested parties can request meetings exclusively through Lake Street Capital Markets. These conferences provide opportunities for investors to gain insights into Castle Biosciences' operations and future plans.